For a study, researchers sought to sum up the PSA response and treatment compliance for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) on apalutamide, both overall and by race.
For the study, 63 urological practices from the United States were represented through electronic medical records. Patients with more or around 2 prescriptions for apalutamide and more or around 12 months of prior prostate cancer treatment were found. Patients were monitored from when apalutamide was started until they switched to another antineoplastic medication, passed away, or the data was no longer available (October 4, 2019). The total treated nmCRPC population’s PSA response (≥50% decline from baseline PSA) and apalutamide adherence rates are given, along with racial stratification (Black and non-Black cohorts).
Apalutamide was started for a total of 193 patients with nmCRPC. Thirty-three patients (17.1%) were Black, 138 were non-Black (71.5%), and the rest were of undetermined racial origin. The mean baseline PSA levels were 7.0 ng/mL overall, 10.5 ng/mL for Black cohorts, and 5.6 ng/mL for non-Black cohorts. At 12 months of follow-up, the PSA response for the overall Black, and non-Black cohorts, was 86.0%, 93.1%, and 85.9%, respectively. For the general Black and non-Black cohorts, adherence was 93.6%, 90.1%, and 94.5% over the course of 333, 352, and 326 days, respectively.
The real-world analysis of nmCRPC patients who had started using apalutamide revealed that the PSA response was strong and consistent with the results of clinical trials. Furthermore, patients of all races showed excellent treatment adherence.